Mankind Pharma Ltd. (MANKIND) AI Stock Analysis

• Market Cap: ₹1.02T
• Dividend Yield: 0.04%
• Average Volume (3M): 10.65K
• Price to Earnings (P/E): 53.3
• Beta (1Y): 0.58
• Revenue Growth: 21.66%
• EPS Growth: -4.92%
• Country: IN
• Employees: 19,540
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.70
• Shares Outstanding: 412,758,480
• 10 Day Avg. Volume: 4,856
• 30 Day Avg. Volume: 10,654
• PEG Ratio: 16.80
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 8.15
• P/FCF Ratio: 50.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,942.50
• Price Target Upside: 20.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 66 Neutral
• Price Target: ₹2,720.00 ▲(11.02% Upside)

Mankind Pharma's strong financial performance is the most significant factor driving the stock score, supported by solid revenue and profit growth. However, the technical analysis indicates mixed signals, and the high P/E ratio raises valuation concerns, which temper the overall score.

Mankind Pharma Ltd. Business Overview & Revenue Model

Company Description

Mankind Pharma Ltd. (MANKIND) is a leading pharmaceutical company based in India, primarily engaged in the development, manufacturing, and marketing of a broad range of pharmaceutical formulations. The company operates in various sectors, including prescription medications, over-the-counter (OTC) products, and veterinary medicine. Mankind Pharma is known for its affordable and high-quality healthcare products, which cater to a wide array of therapeutic areas such as cardiovascular diseases, antibiotics, gastrointestinal, and anti-allergic medications.

How the Company Makes Money

Mankind Pharma Ltd. generates revenue through the sale of its pharmaceutical products, which are distributed both domestically and internationally. The company's key revenue streams include its prescription medicines, OTC products, and veterinary healthcare solutions. Mankind Pharma benefits from a robust distribution network that allows it to reach a wide customer base, including healthcare professionals, hospitals, and pharmacies. Additionally, the company engages in strategic partnerships and collaborations that enhance its market presence and product offerings. By focusing on cost-effective manufacturing and a diverse product portfolio, Mankind Pharma maintains a competitive edge in the pharmaceutical industry, thereby contributing to its financial success.

Mankind Pharma Ltd. Financial Statement Overview

Summary

Mankind Pharma has demonstrated strong financial performance with robust revenue growth and impressive profit margins. The company maintains effective operational efficiency and sound cash flow management, supported by a stable balance sheet with low leverage.

Income Statement

Mankind Pharma has shown robust revenue growth with a significant increase of 18.14% in 2025 compared to 2024. The company's gross profit margin remains strong at 71.41%, and the net profit margin is healthy at 16.31%. EBIT and EBITDA margins are impressive at 49.37% and 24.73%, respectively, showcasing effective operational efficiency.

Balance Sheet

The debt-to-equity ratio is well managed at 0.59, indicating prudent leverage. Return on equity is commendable at 13.89%, reflecting efficient use of equity capital. The equity ratio is strong at 51.62%, ensuring financial stability and low risk. The company's balance sheet reflects a solid financial position with a strong equity base.

Cash Flow

The company exhibits a sound cash flow position with a free cash flow growth rate of 10.32%. The operating cash flow to net income ratio stands at 1.21, demonstrating good cash flow generation capability. The free cash flow to net income ratio is also robust at 0.98, indicating strong cash flow relative to net earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	129.56B	122.07B	103.35B	87.43B	77.82B	62.14B
Gross Profit	84.65B	87.18B	70.14B	33.88B	53.12B	43.89B
EBITDA	34.10B	30.18B	28.09B	20.27B	21.47B	18.17B
Net Income	18.93B	19.91B	19.13B	12.82B	14.33B	12.65B
Balance Sheet
Total Assets	0.00	277.60B	119.63B	97.15B	91.48B	63.73B
Cash, Cash Equivalents and Short-Term Investments	25.25B	22.45B	34.56B	15.29B	12.79B	20.04B
Total Debt	0.00	85.11B	2.07B	1.70B	8.73B	2.41B
Total Liabilities	-145.68B	131.91B	23.87B	20.67B	28.31B	15.10B
Stockholders Equity	145.68B	143.32B	93.63B	74.35B	61.55B	47.22B
Cash Flow
Free Cash Flow	0.00	19.53B	17.70B	9.53B	-14.26B	8.25B
Operating Cash Flow	0.00	24.13B	21.52B	17.85B	9.20B	11.37B
Investing Cash Flow	0.00	-126.92B	-20.82B	-10.54B	-13.69B	-12.22B
Financing Cash Flow	0.00	102.33B	52.66M	-7.40B	6.05B	-78.11M

Mankind Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2450.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Negative. The current price of 2450 is below the 20-day moving average (MA) of 2526.80, below the 50-day MA of 2531.82, and below the 200-day MA of 2497.32, indicating a bearish trend. The MACD of -26.00 indicates Positive momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 52.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANKIND.

Mankind Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	₹621.37B	18.32	―	0.36%	7.76%	-2.84%
TORNTPHARM	72 Outperform	₹1.20T	59.90	―	0.90%	7.63%	15.39%
LUPIN	68 Neutral	₹879.10B	23.74	―	0.63%	12.40%	63.16%
ZYDUSLIFE	67 Neutral	₹993.91B	21.74	―	1.12%	14.52%	9.46%
MANKIND	66 Neutral	₹1.02T	53.29	―	0.04%	21.66%	-4.92%
CIPLA	62 Neutral	₹1.22T	22.67	―	0.86%	6.40%	25.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mankind Pharma Ltd. Corporate Events

Mankind Pharma Releases Q1 FY26 Investor Call Transcript

Mankind Pharma Ltd. released the transcript of its Q1 FY26 investor conference call, highlighting the company’s financial performance and strategic direction. The call, led by key executives, provided insights into the company’s operations and market positioning, potentially impacting stakeholders’ perspectives on its future growth and industry influence.

Mankind Pharma Seeks Reclassification of Promoter Group

Mankind Pharma Ltd. has submitted an application to reclassify Ayushi and Poonam Estates LLP from the ‘Promoter & Promoter Group’ category to the ‘Public’ category. This move is part of the company’s strategic efforts to align with regulatory requirements and potentially enhance its market positioning by broadening its public shareholder base.

Mankind Pharma to Review Financials and Consider Interim Dividend

Mankind Pharma Ltd. has announced a Board meeting scheduled for July 31, 2025, to discuss and approve the unaudited financial results for the quarter ending June 30, 2025, and to consider the declaration of an interim dividend for the financial year 2025-26. The trading window for the company’s securities will remain closed until August 2, 2025, as per insider trading regulations, which may impact stakeholders’ trading activities.

Mankind Pharma Schedules Board Meeting to Review Financials and Consider Dividend

Mankind Pharma Ltd. has announced a scheduled board meeting on July 31, 2025, to review and approve the unaudited financial results for the quarter ending June 30, 2025, and to consider declaring an interim dividend for the financial year 2025-26. In compliance with SEBI regulations, the company has closed its trading window until August 2, 2025, to prevent insider trading, reflecting its adherence to regulatory standards and commitment to transparency.